A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint

被引:0
|
作者
Qing, Yun [1 ,2 ]
Thall, Peter F. [1 ]
Yuan, Ying [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Houston, TX 77030 USA
关键词
Bayesian adaptive design; futility monitoring; go; no-go decision; interim analysis; OPTIMAL 2-STAGE DESIGNS; CLINICAL-TRIALS; SURVIVAL; SAMPLE;
D O I
10.1002/pst.2256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A robust Bayesian design is presented for a single-arm phase II trial with an early stopping rule to monitor a time to event endpoint. The assumed model is a piecewise exponential distribution with non-informative gamma priors on the hazard parameters in subintervals of a fixed follow up interval. As an additional comparator, we also define and evaluate a version of the design based on an assumed Weibull distribution. Except for the assumed models, the piecewise exponential and Weibull model based designs are identical to an established design that assumes an exponential event time distribution with an inverse gamma prior on the mean event time. The three designs are compared by simulation under several log-logistic and Weibull distributions having different shape parameters, and for different monitoring schedules. The simulations show that, compared to the exponential inverse gamma model based design, the piecewise exponential design has substantially better performance, with much higher probabilities of correctly stopping the trial early, and shorter and less variable trial duration, when the assumed median event time is unacceptably low. Compared to the Weibull model based design, the piecewise exponential design does a much better job of maintaining small incorrect stopping probabilities in cases where the true median survival time is desirably large.
引用
收藏
页码:34 / 44
页数:11
相关论文
共 50 条
  • [1] A Bayesian adaptive design for biosimilar trials with time-to-event endpoint
    Belay, Sheferaw Y.
    Mu, Rongji
    Xu, Jin
    PHARMACEUTICAL STATISTICS, 2021, 20 (03) : 597 - 609
  • [2] Bayesian optimal phaseIIclinical trial design with time-to-event endpoint
    Zhou, Heng
    Chen, Cong
    Sun, Linda
    Yuan, Ying
    PHARMACEUTICAL STATISTICS, 2020, 19 (06) : 776 - 786
  • [3] Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint
    Yin G.
    Chen N.
    Lee J.J.
    Statistics in Biosciences, 2018, 10 (2) : 420 - 438
  • [4] TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy
    Lin, Ruitao
    Coleman, Robert L.
    Yuan, Ying
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (01): : 38 - 45
  • [5] Milestone prediction for time-to-event endpoint monitoring in clinical trials
    Ou, Fang-Shu
    Heller, Martin
    Shi, Qian
    PHARMACEUTICAL STATISTICS, 2019, 18 (04) : 433 - 446
  • [6] Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint
    Huang, Bo
    Talukder, Enayet
    Han, Lixin
    Kuan, Pei-Fen
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (01) : 189 - 202
  • [7] A phase II trial design based on median time-to-event
    Karrison, T
    Rudin, C
    CONTROLLED CLINICAL TRIALS, 2003, 24 : 225S - 225S
  • [8] Bayesian Phase II optimization for time-to-event data based on historical information
    Bertsche, Anja
    Fleischer, Frank
    Beyersmann, Jan
    Nehmiz, Gerhard
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2019, 28 (04) : 1272 - 1289
  • [9] A seamless Phase I/II platform design with a time-to-event efficacy endpoint for potential COVID-19 therapies
    Jaki, Thomas
    Barnett, Helen
    Titman, Andrew
    Mozgunov, Pavel
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2024, 33 (11-12) : 2115 - 2130
  • [10] Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials
    Yuan, Ying
    Lin, Ruitao
    Li, Daniel
    Nie, Lei
    Warren, Katherine E.
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 4921 - 4930